HC Wainwright Analysts Boost Earnings Estimates for ALDX

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Research analysts at HC Wainwright upped their Q1 2026 earnings per share estimates for Aldeyra Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright analyst M. Caufield now anticipates that the biotechnology company will earn ($0.13) per share for the quarter, up from their prior estimate of ($0.15). The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for Aldeyra Therapeutics’ Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at $0.27 EPS, FY2026 earnings at ($0.15) EPS, FY2028 earnings at $0.79 EPS, FY2029 earnings at $1.08 EPS and FY2030 earnings at $1.04 EPS.

Separately, BTIG Research reissued a “buy” rating and issued a $9.00 target price on shares of Aldeyra Therapeutics in a research report on Monday, November 10th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $9.50.

Aldeyra Therapeutics Price Performance

ALDX stock opened at $4.65 on Friday. The stock has a market capitalization of $279.84 million, a P/E ratio of -8.16 and a beta of 0.97. Aldeyra Therapeutics has a 1-year low of $1.14 and a 1-year high of $7.20. The business has a fifty day moving average price of $5.02 and a 200-day moving average price of $5.17.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of ALDX. Invesco Ltd. increased its position in shares of Aldeyra Therapeutics by 22.0% during the 4th quarter. Invesco Ltd. now owns 163,087 shares of the biotechnology company’s stock valued at $845,000 after purchasing an additional 29,382 shares during the last quarter. XTX Topco Ltd increased its holdings in Aldeyra Therapeutics by 22.5% during the fourth quarter. XTX Topco Ltd now owns 42,227 shares of the biotechnology company’s stock valued at $219,000 after buying an additional 7,761 shares during the last quarter. Caption Management LLC bought a new position in Aldeyra Therapeutics in the fourth quarter worth approximately $181,000. 683 Capital Management LLC boosted its stake in shares of Aldeyra Therapeutics by 86.6% during the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock worth $7,925,000 after acquiring an additional 710,000 shares during the last quarter. Finally, ACT Capital Management LLC bought a new stake in shares of Aldeyra Therapeutics during the 4th quarter valued at $212,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS outlook sharply (from -$0.35 to -$0.15) and bumped the Q4 2026 estimate to $0.27; it also slightly improved the Q1 2026 loss estimate (from -$0.15 to -$0.13). These upward revisions suggest the analyst sees a nearer‑term path toward breakeven/profitability. MarketBeat ALDX analyst note
• Neutral Sentiment: Reported short‑interest data for early March shows “0 shares” and a 0.0 days‑to‑cover metric — likely a data/reporting anomaly rather than a meaningful shift in short positioning. That reduces the likelihood short squeezes or covering drove today’s move. MarketBeat short interest report
• Negative Sentiment: HC Wainwright trimmed several near‑ and longer‑term estimates: Q2 2026 (from -$0.15 to -$0.16), Q3 2026 (from -$0.08 to -$0.13), FY2027 (from $0.11 to $0.08), and cut FY2028 and FY2029 forecasts materially (FY2028: $0.95 → $0.79; FY2029: $1.25 → $1.08). Those downward revisions to future growth/profitability likely weigh on investor sentiment and explain part of the share decline today. MarketBeat ALDX analyst note

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.